|
|
|
|
| LEADER |
06220nma a2201729 u 4500 |
| 001 |
EB001979816 |
| 003 |
EBX01000000000000001142718 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783039213924
|
| 020 |
|
|
|a 9783039213917
|
| 020 |
|
|
|a books978-3-03921-392-4
|
| 100 |
1 |
|
|a Brüssow, Harald
|
| 245 |
0 |
0 |
|a Hurdles for Phage Therapy (PT) to Become a Reality
|h Elektronische Ressource
|
| 260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2019
|
| 300 |
|
|
|a 1 electronic resource (484 p.)
|
| 653 |
|
|
|a Staphylococcus
|
| 653 |
|
|
|a foodborne illness
|
| 653 |
|
|
|a viral genomes
|
| 653 |
|
|
|a E. faecalis
|
| 653 |
|
|
|a zoonosis
|
| 653 |
|
|
|a bacteriophage
|
| 653 |
|
|
|a prophage
|
| 653 |
|
|
|a nontraditional antibacterial
|
| 653 |
|
|
|a typhoid fever
|
| 653 |
|
|
|a phage-resistance
|
| 653 |
|
|
|a Bacteriophage
|
| 653 |
|
|
|a Galleria mellonella
|
| 653 |
|
|
|a extended-spectrum beta lactamases (ESBL)
|
| 653 |
|
|
|a immunology
|
| 653 |
|
|
|a Democratic Republic of the Congo
|
| 653 |
|
|
|a rhamnopolysaccharide
|
| 653 |
|
|
|a bacterial infection
|
| 653 |
|
|
|a antimicrobial resistance
|
| 653 |
|
|
|a therapy
|
| 653 |
|
|
|a human host
|
| 653 |
|
|
|a Staphylococcus aureus
|
| 653 |
|
|
|a capsule depolymerase
|
| 653 |
|
|
|a Twortlikevirus
|
| 653 |
|
|
|a sustainable agriculture
|
| 653 |
|
|
|a antimicrobial resistance (AMR)
|
| 653 |
|
|
|a Listeria ivanovii
|
| 653 |
|
|
|a gastrointestinal tract
|
| 653 |
|
|
|a Brussels
|
| 653 |
|
|
|a antibiotic
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a phage biocontrol
|
| 653 |
|
|
|a history of science
|
| 653 |
|
|
|a experimental therapy
|
| 653 |
|
|
|a phagodisinfection
|
| 653 |
|
|
|a bacteriophage therapy
|
| 653 |
|
|
|a antibiotic resistance
|
| 653 |
|
|
|a industrial phage application
|
| 653 |
|
|
|a frequency of resistance
|
| 653 |
|
|
|a production
|
| 653 |
|
|
|a phages
|
| 653 |
|
|
|a adaptation
|
| 653 |
|
|
|a adaptive immunity
|
| 653 |
|
|
|a ATMP
|
| 653 |
|
|
|a phage-human host interaction
|
| 653 |
|
|
|a evolution
|
| 653 |
|
|
|a compassionate use
|
| 653 |
|
|
|a immunomodulation
|
| 653 |
|
|
|a compounding pharmacy
|
| 653 |
|
|
|a adsorption
|
| 653 |
|
|
|a Salmonella Typhi
|
| 653 |
|
|
|a antibiotic therapy
|
| 653 |
|
|
|a multidrug-resistant bacteria
|
| 653 |
|
|
|a regulation
|
| 653 |
|
|
|a global health
|
| 653 |
|
|
|a patent landscape
|
| 653 |
|
|
|a innate immunity
|
| 653 |
|
|
|a virulence
|
| 653 |
|
|
|a Germany
|
| 653 |
|
|
|a pharmaceutical legislation
|
| 653 |
|
|
|a Pseudomonas aeruginosa
|
| 653 |
|
|
|a antibiotic-resistance
|
| 653 |
|
|
|a Klebsiella pneumoniae
|
| 653 |
|
|
|a resistance
|
| 653 |
|
|
|a disinfection
|
| 653 |
|
|
|a genomics
|
| 653 |
|
|
|a bacteriophage efficacy
|
| 653 |
|
|
|a capsule
|
| 653 |
|
|
|a anti-phage antibodies
|
| 653 |
|
|
|a antimicrobial
|
| 653 |
|
|
|a phage preparation
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a bacterial resistance
|
| 653 |
|
|
|a phage-host interactions
|
| 653 |
|
|
|a personalised medicines
|
| 653 |
|
|
|a phage
|
| 653 |
|
|
|a MALDI-MS
|
| 653 |
|
|
|a food safety
|
| 653 |
|
|
|a infection
|
| 653 |
|
|
|a Escherichia coli
|
| 653 |
|
|
|a virus-host interactions
|
| 653 |
|
|
|a phage therapy
|
| 653 |
|
|
|a crop production
|
| 653 |
|
|
|a phage cocktails
|
| 653 |
|
|
|a bacterial disease
|
| 653 |
|
|
|a lysins
|
| 653 |
|
|
|a IND
|
| 653 |
|
|
|a bacteriophages
|
| 653 |
|
|
|a alginate
|
| 653 |
|
|
|a biofilm
|
| 653 |
|
|
|a personalized medicine
|
| 653 |
|
|
|a OrthoMCL
|
| 653 |
|
|
|a pH stability
|
| 653 |
|
|
|a biofilms
|
| 653 |
|
|
|a pharmaceutical paradigm shift
|
| 653 |
|
|
|a target selection
|
| 653 |
|
|
|a regulatory framework
|
| 653 |
|
|
|a Viral proteins
|
| 653 |
|
|
|a magistral preparation
|
| 653 |
|
|
|a science communication
|
| 653 |
|
|
|a PTMP
|
| 653 |
|
|
|a best practices
|
| 653 |
|
|
|a Belgium
|
| 653 |
|
|
|a Kayvirus
|
| 653 |
|
|
|a infectious disease
|
| 653 |
|
|
|a abortive infection
|
| 653 |
|
|
|a horizontal gene transfer
|
| 653 |
|
|
|a clinical trial
|
| 653 |
|
|
|a phage sensitivity
|
| 653 |
|
|
|a cases report
|
| 653 |
|
|
|a magistral formula
|
| 653 |
|
|
|a vB_SauM-fRuSau02
|
| 653 |
|
|
|a co-evolution
|
| 653 |
|
|
|a high-throughput sequencing
|
| 653 |
|
|
|a developing countries
|
| 653 |
|
|
|a resistance management
|
| 653 |
|
|
|a Enterococcus
|
| 653 |
|
|
|a animal model
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03921-392-4
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/1504
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/49693
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 576
|
| 082 |
0 |
|
|a 900
|
| 082 |
0 |
|
|a 630
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 380
|
| 520 |
|
|
|a Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage-bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.
|